Prevenzione della fibrillazione atriale post-operatoria utilizzando la combinazione di CardiaMend e Amiodarone (CAMP POAF)

Inclusion Criteria:

• Subject aged 20-85 years old.

• Patients able to provide written informed consent, understand, and be willing to comply with study-related procedures.

• Participants who are scheduled to undergo open-chest cardiac surgery via complete median sternotomy. Includes:

  • Coronary artery bypass graft (CABG) or valve repair/replacement, or
  • Inclusionary valve repair/replacement procedures for the primary reason for surgery include: aortic valve repair/replacement, mitral valve repair/replacement.
  • Note: Left atrial appendage (LAA) procedures are allowed if CABG and/or valve repair or replacement is the qualifying surgical procedure, but is not a qualifying surgical procedure on its own.

• In sinus rhythm at the time of office visit and prior EKG (note: continuous EKG monitoring for 48 hours is not required).

Exclusion Criteria:

• Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalized by court or official order, or in a dependency relationship with, testing center or investigator.
• Any condition which could interfere with the subject's ability to comply with the study.
• Ongoing participation in an interventional clinical study or during the preceding 30 days.
• Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the course of the study.
• Active skin or deep infection at the site of implantation.
• History of chronic wounds or wound-healing disorders.
• Known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta).
• Immune-suppressed subjects, immune-deficiency subjects (properly managed diabetes mellitus is not an exclusion criterion).
• Concomitant oral or IV systemic corticosteroid therapy and/or other constant anti-inflammatory therapies.
• The subject has an implantable cardiac device (i.e., cardiac resynchronization therapy devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable cardioverter-defibrillators (ICD) and pacemakers).
• Known history of atrial fibrillation or paroxysmal atrial fibrillation.
• History of ablation for atrial fibrillation.
• Patients already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias.
• Disease of the left pleura, previous intervention in the left pleural space, or chest deformity.
• Subjects with end-stage chronic-renal disease / dialysis.
• Subjects with heart failure (BNP>1000), low ejection fraction (<35%), end stage renal disease (on dialysis or creatinine >1.8).
• STS risk >5.5% for 30 day mortality.
• Patients electing to receive an ablative procedure for atrial fibrillation during the index operation.